Fibrocel Science

FCSC NASDAQ
1.875
+0.035
+1.90%
Closed 16:00 05/24 EDT
Open
1.800
Prev Close
1.840
High
1.900
Low
1.800
Volume
42.68K
Avg Vol (3M)
962.91K
52 Week High
5.17
52 Week Low
1.450
% Turnover
0.44%
Market Cap
18.25M
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Company Profile

Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.
MORE >

Recently

Name
Price
%Change